Jun-Hyung Cho

Dr. Jun-Hyung Cho

Soonchunhyang University Seoul Hospital
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2018 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Jun-Hyung ChoJun-Hyung Cho
Jun-Hyung Cho
SJSeong Ran Jeon
Seong Ran Jeon
HKHyun Gun Kim
Hyun Gun Kim
SJSo‐Young Jin
So‐Young Jin
SPSuyeon Park
Suyeon Park

6 July 2022 in World Journal of Clinical Cases
Verified
Journal Article
Open access
Jun-Hyung ChoJun-Hyung Cho
Jun-Hyung Cho
SJSo-Young Jin
So-Young Jin
Helicobacter pylori (H. pylori) infection is highly prevalent in East Asia. The overall seroprevalence rate of H. pylori infection is 44.2% in China, 37.6%-43.2% in Japan, and 51.0% in South Korea. H. pylori can cause peptic ulcer disease and gastric cancer. East Asian countries have high rates of gastric cancer (age-standardized incidence rate: 20-30 per 100000). The Kyoto global consensus report emphasized that H. pylori gastritis should be considered the main cause for the development of gastric cancer. H. pylori treatment guidelines in China, Japan, and South Korea have recently been revised according to data from each of those countries. However, emerging antibiotic resistance is an important barrier to H. pylori eradication. The recommended H. pylori treatment regimens differ among those three East Asian countries. In this review, recent guidelines and up-to-date research on H. pylori treatment regimens from China, Japan, and South Korea are discussed.


28 November 2012 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
Jun-Hyung ChoJun-Hyung Cho
Jun-Hyung Cho
YCYoung Woon Chang
Young Woon Chang
JJJae Young Jang
Jae Young Jang
JSJae‐Jun Shim
Jae‐Jun Shim
CLChang Kyun Lee
Chang Kyun Lee
JCJoo Young Cho
Joo Young Cho

30 January 2021 in Intestinal Research
Verified
Journal Article
Open access
PDF file
YJYujin Jeong
Yujin Jeong
Seong Ran JeonSeong Ran Jeon
Seong Ran Jeon
HKHyun Gun Kim
Hyun Gun Kim
JMJung Rock Moon
Jung Rock Moon
TLTae Hee Lee
Tae Hee Lee
SPSuyeon Park
Suyeon Park
Background/Aims: Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can serve as biomarkers for diagnosing and assessing disease activity in ulcerative colitis (UC). We investigated their clinical significance in UC.Methods: We analyzed 48 patients with UC who underwent measurement of fecal calprotectin (FC) and endoscopy and 96 age- and sex-matched healthy controls. NLR and PLR were compared between the patients and healthy controls. The endoscopic activity was divided into 2 groups: group 1 (mild to moderate inflammation) and group 2 (severe inflammation) according to the Mayo endoscopic subscore in UC.Results: To diagnose UC, the optimal cutoff of NLR and PLR was 2.26 (sensitivity 54.2%; specificity 90.6%; positive likelihood ratio 5.778, 95% confidence interval [CI] 2.944–11.339; area under the curve [AUC] 0.774, 95% CI, 0.690–0.859) and 179.8 (sensitivity 35.4%; specificity 90.6%; positive likelihood ratio 3.778, 95% CI 1.821–7.838; AUC 0.654, 95% CI 0.556–0.753), respectively. The optimal cutoff to differentiate group 1 and group 2 was 3.44, 175.9, and 453 µg/g for NLR, PLR, and FC, respectively (sensitivity, 63.6% vs. 90.9% vs. 81.8%; specificity, 81.1% vs. 78.4% vs. 73.0%; positive likelihood ratio, 3.364 vs. 4.205 vs. 3.027; AUC, 0.714 vs. 0.897 vs. 0.813). PLR had the highest AUC and positive likelihood ratio.Conclusions: NLR and PLR help differentiate patients with UC from healthy controls. NLR, PLR, and FC indicate endoscopic activity and may reflect intestinal mucosal conditions.

20 December 2021 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
Jun-Hyung ChoJun-Hyung Cho
Jun-Hyung Cho
SJSo-Young Jin
So-Young Jin
SPSuyeon Park
Suyeon Park
We aimed to compare the success rate, adverse drug events, and cost-effectiveness of tailored Helicobacter pylori eradication and modified bismuth-containing quadruple therapy.The diagnosis of H. p...